BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...Phosphoinositide 3-kinaseRET – Ret proto-oncogene Paul Bonanos PLX8394 Novellus Ltd. NovellusDx Ltd. Fore...
BioCentury | Sep 21, 2018
Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

...Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders will...
...will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s...
...NovellusDx Ltd., Jerusalem, Israel Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic, Cancer Jaime De Leon Cancer Genetics Inc. NovellusDx Ltd....
BioCentury | Feb 9, 2015
Emerging Company Profile

Signal mapping

...cytoplasm to the nucleus to stimulate cell proliferation. "Passenger" mutations don't result in nuclear translocation. NovellusDx's...
...mutations in a patient's tumor result in translocation to distinguish the passenger and driver mutations. NovellusDx...
...and Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. NovellusDx Ltd., Jerusalem, Israel Sidebars NovellusDx Ltd....
Items per page:
1 - 3 of 3
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...Phosphoinositide 3-kinaseRET – Ret proto-oncogene Paul Bonanos PLX8394 Novellus Ltd. NovellusDx Ltd. Fore...
BioCentury | Sep 21, 2018
Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

...Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders will...
...will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s...
...NovellusDx Ltd., Jerusalem, Israel Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic, Cancer Jaime De Leon Cancer Genetics Inc. NovellusDx Ltd....
BioCentury | Feb 9, 2015
Emerging Company Profile

Signal mapping

...cytoplasm to the nucleus to stimulate cell proliferation. "Passenger" mutations don't result in nuclear translocation. NovellusDx's...
...mutations in a patient's tumor result in translocation to distinguish the passenger and driver mutations. NovellusDx...
...and Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. NovellusDx Ltd., Jerusalem, Israel Sidebars NovellusDx Ltd....
Items per page:
1 - 3 of 3